CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway

Area of Science:

• Immunology
• Cellular Biology

Background:

• CD33 (siglec-3) is an inhibitory sialoadhesin on myeloid cells and some lymphoid subsets, including NK cells.
• Its precise inhibitory function, particularly on NK cells, remains incompletely understood.
• CD33 is a known target in leukemia therapy, highlighting its clinical relevance.

Purpose of the Study:

• To investigate the inhibitory function of CD33 on human NK cells.
• To determine how CD33 modulates cytotoxicity triggered by various activating receptors.
• To elucidate the signaling pathways involved in CD33-mediated inhibition.

Main Methods:

• Utilized human NK cells (NKL cell lines) with varying cytotoxicity.
• Analyzed CD33's inhibitory effect on cytotoxicity induced by NKG2D, 2B4, and NKp46 activating receptors.
• Assessed IFN-γ secretion and Vav1 dephosphorylation upon CD33 triggering.

Main Results:

• CD33 prominently inhibited NKG2D- and partially 2B4-induced cytotoxicity in high-cytotoxicity NKL cells.
• CD33 did not inhibit NKp46-induced cytotoxicity, nor IFN-γ secretion.
• CD33-mediated inhibition of NKG2D involved Vav1 dephosphorylation, suggesting regulation of the NKG2D/DAP10 pathway.

Conclusions:

• CD33 functions as an inhibitory receptor on NK cells, preferentially regulating the NKG2D/DAP10 pathway.
• This inhibitory role may contribute to immune self-tolerance and the recognition of tumor or infected cells.
• CD33's inhibitory mechanism differs from other NK cell inhibitory receptors like ILT-2 and CD94/NKG2A.